mardi 4 décembre 2018

Onco Actu du 4 décembre 2018 - Spécial ASH

5.8 ASH

ASH Highlights for Monday, December 3, 2018 [OBR]

5.8.2 ASH - Pharma

ASH 2018: Three Up, Two Down As The Big Blood Disease Meeting Rolls On [Xconomy]

5.8.4 ASH - CAR T

Kite Announces Updated Data From ZUMA-3 Study of KTE-X19 in Adult Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia [Gilead]

ASH18: Legend's CAR-T brought back to reality [BiopharmaDive]

Off-the-shelf cell therapy for cancer? Fate Therapeutics to make its case at ASH [FierceBiotech]

Study shows promise for fighting relapsed blood cancer with CAR-T immunotherapy, chemotherapy [UNC]

Celgene Corporation Announces Initial Clinical Data from Ongoing Phase 1/2 Evolve Trial with Anti-BCMA CAR T Therapy JCARH125 in Relapsed/Refractory Multiple Myeloma at ASH 2018 [Celgene]

#ASH18: Legend Biotech — allied with J&J now — continues to wow the crowd with their BCMA CAR-T update. What will bluebird say? [EndPoints]

Ash 2018 – Legend’s mystery CAR raises more questions [Vantage]

'Exciting' but early results in trial of immunotherapy for myeloma [Fred Hutch]

#ASH18: Allogene ticks off a high CR rate for updated off-the-shelf CAR-T pioneer. But getting just the right kind of immunosuppression is crucial [EndPoints]

CAR T therapies show durable responses, potential benefits from combinations [Bio World]

5.8.5 ASH - Myélome multiple

Amgen Announces First-In-Human Data Evaluating Investigational Novel BiTE® Immunotherapies AMG 420 And AMG 330 At ASH 2018 [Amgen]

Updated Data from Phase 1/2 Open-Label Study of BCMA-Directed CAR-T Cell Therapy LCAR-B38M Show Tolerable Safety Profile, High Overall Response and MRD Negative Rate in Treatment of Patients with Advanced Relapsed or Refractory Multiple Myeloma [Janssen]

Amgen antibody shows promise in myeloma trial, gets FDA fast track [Reuters]

#ASH18: Can Amgen break through the BCMA CAR-T line and take a BiTE of the multiple myeloma market? It won’t be quick or easy [EndPoints]

5.8.6 ASH - Leucémies

New Venclexta/Venclyxto data demonstrate deep responses in two of the most common types of leukaemia [Roche]

5.8.7 ASH - Lymphomes

Seattle Genetics rolls into latest Adcetris launch with double survival win [FiercePharma]

Regeneron records 80% complete response rate in lymphoma trial [FierceBiotech]

Seattle Genetics and Takeda Present Positive Data from Phase 3 ECHELON-2 Clinical Trial for ADCETRIS® (Brentuximab Vedotin) in Frontline Treatment of CD30-Expressing Peripheral T-Cell Lymphomas [Takeda]

New long-term data on Calquence presented at ASH 2018 [AstraZeneca]

IMBRUVICA® (ibrutinib) Plus Obinutuzumab Showed Significant Improvement in Progression-Free Survival Compared to Chlorambucil Plus Obinutuzumab in Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma [Johnson&Johnson]

#ASH18: BeiGene works to bust through the checkpoint crowd with a pivotal readout that proves its PD-1 is better than the rest [EndPoints]